Pyrimidine Derivative Salts for Mutant EGFR Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new EGFR inhibitors, additional stable forms of EGFR inhibitors, and improved manufacturing processes for preparing EGFR inhibitors to address the stability and reproducibility issues in pharmaceutical compounds, particularly for treating cancers associated with mutant EGFR mutations.
Innovation Solution
The development of a process for preparing novel polymorphic forms and pharmaceutical salts of EGFR inhibitors, such as Compound (A) and its succinate salt, which includes specific synthetic methods and dosing regimens for administering these forms to achieve therapeutic effectiveness in treating cancers like non-small cell lung cancer and other EGFR-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional manufacturing processes are used to prepare EGFR inhibitors, then the production can be maintained, but the stability and reproducibility of the active substance is compromised
Solution Approach 1:
The patent employs parameter changes by optimizing reaction conditions including temperature ranges (0°C to room temperature), solvent selections (dichloromethane, ethyl acetate, isopropyl acetate), and pH control during salt formation to achieve stable crystalline forms with improved reproducibility and manufacturing reliability
Solution Approach 2:
The patent utilizes phase transitions through controlled crystallization processes where the active substance transitions from solution phase to solid crystalline phase, establishing stable polymorphic forms that ensure consistent processing parameters and improved manufacturing reliability
2Manufacturing precision
If unstable active substances are used, then the manufacturing process may be simpler, but the final formulations do not meet quality requirements
Solution Approach 1:
The patent applies preliminary action by pre-establishing stable crystalline forms and pharmaceutically acceptable salts of the active substance before formulation development, ensuring that the starting material possesses the required stability and purity to meet final product quality specifications
Solution Approach 2:
The patent replaces mechanical mixing and processing with controlled chemical processes including in-situ salt formation and crystallization, which provide more precise control over the physical and chemical properties of the active substance, thereby improving manufacturing precision and quality consistency
3Reliability
If new polymorphic forms and salts are developed, then stability and quality are improved, but the development time and process complexity increase
Solution Approach 1:
The patent segments the development process into distinct modules: salt formation screening, polymorph identification, crystallization optimization, and formulation development. This systematic segmentation allows for efficient progression through development stages while maintaining quality standards
Solution Approach 2:
The patent develops pharmaceutically acceptable salts that serve multiple functions: improving stability, enhancing solubility, facilitating crystallization, and enabling formulation flexibility. This multi-functionality reduces the need for separate development programs for different critical quality attributes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel polymorphic forms and salts of EGFR inhibitors provide stable and effective treatments for cancers with mutant EGFR mutations, ensuring consistent processing parameters and pharmaceutical quality, and achieving therapeutic plasma concentrations for extended periods.
Implementation Method 1
mixing Compound (A) with succinic acid in the presence of a solvent; heating the mixture of step (a)
Implementation Method 2
heating the mixture of step (a)
Implementation Method 3
novel polymorphic forms of Compound (A) and processes for the preparation thereof
Data Source
AI summary
The present disclosure relates to pharmaceutical salts and polymorphic forms of pyrimidine derivatives that have inhibitory activities against mutant epidermal growth factor receptor (EGFR). The present disclosure further relates to the processes for the preparation of the pyrimidine derivatives and to the pharmaceutical salts and the polymorphic forms of the pyrimidine derivatives.